COMMUNIQUÉS West-GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock
02/12/2024
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
02/12/2024
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
MacroGenics to Participate in Upcoming Investor Conference
02/12/2024
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody- [...]
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
02/12/2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024
02/12/2024
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Treace Appoints Guy Guglielmino as Chief Commercial Officer
02/12/2024
PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Certara Showcases 2024 Research Wins With Over 100 Papers Published
02/12/2024
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed [...]
Capricor Therapeutics to Present at Upcoming Investor Conferences
02/12/2024
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
02/12/2024
Reimbursement approval supports expanded access to effective, safe thrombus removal for patients suffering from deep vein thrombosis (DVT) in Japan IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. ( [...]
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
02/12/2024
Upon closing, the transaction would secure global IP rights for NKGen. NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer (“NK”) cell therapy is already [...]
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
02/12/2024
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral [...]
Inari Medical Announces Joint Venture in Greater China
02/12/2024
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]
OrthoPediatrics Corp. to Host Educational and Networking Events at 20th Annual International Pediatric Orthopaedic Symposium (IPOS)
02/12/2024
Continues IPOS Corporate Partnership as Emerald-Level Sponsor WARSAW, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on [...]
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
02/12/2024
HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today [...]
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
02/12/2024
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
02/12/2024
Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in [...]
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
02/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart’s oral pill COVID [...]
Cytokinetics to Participate in December Investor Conferences
02/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following December investor conferences: 7 th [...]
M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation
02/12/2024
TOKYO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A [...]

Pages